Pfizer's eczema treatment shows promising results in multiple mid-stage trials

Pfizer announced positive Phase 2 results for tilrekimig (PF-07275315), a first-in-class trispecific antibody targeting IL-4, IL-13, and TSLP simultaneously, in patients with moderate-to-severe atopic dermatitis. The study met its primary endpoint, demonstrating statistically significant EASI-75 response rates at Week 16 versus placebo, with placebo-adjusted rates of 38.7% (low dose), 51.9% (mid dose), and 49.4% (high dose). The treatment was well-tolerated with adverse event rates comparable to placebo.

The results set up a direct challenge to Sanofi and Regeneron's Dupixent, which posted $17.8 billion in global sales in 2025 and dominates the atopic dermatitis market. Unlike Dupixent, which targets only IL-4 and IL-13, tilrekimig adds TSLP as a third target and is designed as a once-monthly injection versus Dupixent's biweekly dosing — a potential convenience advantage. PFE already markets Cibinqo (abrocitinib), an oral JAK inhibitor for eczema, and tilrekimig would complement that portfolio as a biologic option. The broader atopic dermatitis treatment market is estimated at $21–23 billion in 2026 and forecast to reach $32–33 billion by 2032.

Pfizer said it is accelerating Phase 3 plans, with a pivotal study expected to launch later in 2026. However, PFE shares showed little immediate reaction, trading at $26.60 on March 9 — the market may be pricing in the long timeline to commercialization, with FDA approval unlikely before 2028–2029 at the earliest. Competitors in the space include Eli Lilly's Ebglyss (once-monthly) and AbbVie's Rinvoq, making the path to market share a crowded one despite tilrekimig's differentiated mechanism.